FACEPHI BIOMETRIA SA (ALPHI.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALPHI - ES0105029005 - Common Stock
2.5 EUR
-0.14 (-5.3%)
ALPHI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 107 industry peers in the Software industry. ALPHI may be in some trouble as it scores bad on both profitability and health. ALPHI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ALPHI had negative earnings in the past year.
In the past year ALPHI had a positive cash flow from operations.
In the past 5 years ALPHI reported 4 times negative net income.
In multiple years ALPHI reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -17.87%, ALPHI is not doing good in the industry: 84.11% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -46.29%, ALPHI is doing worse than 81.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.87% | ||
| ROE | -46.29% | ||
| ROIC | N/A |
ROA(3y)-7.96%
ROA(5y)-7.7%
ROE(3y)-20.17%
ROE(5y)-18.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ALPHI (51.01%) is worse than 66.36% of its industry peers.
In the last couple of years the Gross Margin of ALPHI has declined.
The Profit Margin and Operating Margin are not available for ALPHI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.69%
GM growth 5Y-11.48%
2. Health
2.1 Basic Checks
ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPHI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALPHI has more shares outstanding
The debt/assets ratio for ALPHI has been reduced compared to a year ago.
2.2 Solvency
ALPHI has an Altman-Z score of 1.12. This is a bad value and indicates that ALPHI is not financially healthy and even has some risk of bankruptcy.
ALPHI has a Altman-Z score of 1.12. This is in the lower half of the industry: ALPHI underperforms 70.09% of its industry peers.
ALPHI has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.05, ALPHI is doing good in the industry, outperforming 79.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.12 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
A Current Ratio of 1.08 indicates that ALPHI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.08, ALPHI is doing worse than 64.49% of the companies in the same industry.
ALPHI has a Quick Ratio of 1.08. This is a normal value and indicates that ALPHI is financially healthy and should not expect problems in meeting its short term obligations.
ALPHI has a Quick ratio of 1.08. This is in the lower half of the industry: ALPHI underperforms 61.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
ALPHI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.15%.
Looking at the last year, ALPHI shows a quite strong growth in Revenue. The Revenue has grown by 14.80% in the last year.
Measured over the past years, ALPHI shows a very strong growth in Revenue. The Revenue has been growing by 28.65% on average per year.
EPS 1Y (TTM)-51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-686.71%
Revenue 1Y (TTM)14.8%
Revenue growth 3Y29.94%
Revenue growth 5Y28.65%
Sales Q2Q%11.54%
3.2 Future
Based on estimates for the next years, ALPHI will show a very strong growth in Earnings Per Share. The EPS will grow by 52.48% on average per year.
The Revenue is expected to grow by 12.07% on average over the next years. This is quite good.
EPS Next Y105%
EPS Next 2Y52.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.32%
Revenue Next 2Y20.88%
Revenue Next 3Y16.2%
Revenue Next 5Y12.07%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 183.87, which means the current valuation is very expensive for ALPHI.
Based on the Price/Forward Earnings ratio, ALPHI is valued a bit more expensive than the industry average as 65.42% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 34.46. ALPHI is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 183.87 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ALPHI's earnings are expected to grow with 52.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.48%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALPHI (11/21/2025, 7:00:00 PM)
2.5
-0.14 (-5.3%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners28.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap64.45M
Revenue(TTM)28.88M
Net Income(TTM)-8.88M
Analysts82.5
Price Target3.24 (29.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.86%
PT rev (3m)6.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)122.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-11.49%
Revenue NY rev (3m)-11.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 183.87 | ||
| P/S | 2.23 | ||
| P/FCF | N/A | ||
| P/OCF | 88.97 | ||
| P/B | 3.36 | ||
| P/tB | 8.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.37
EYN/A
EPS(NY)0.01
Fwd EY0.54%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.03
OCFY1.12%
SpS1.12
BVpS0.74
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.87% | ||
| ROE | -46.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.01% | ||
| FCFM | N/A |
ROA(3y)-7.96%
ROA(5y)-7.7%
ROE(3y)-20.17%
ROE(5y)-18.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.69%
GM growth 5Y-11.48%
F-Score5
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 93.96% | ||
| Cap/Sales | 18.19% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 1.12 |
F-Score5
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)134.96%
Cap/Depr(5y)175.34%
Cap/Sales(3y)22.22%
Cap/Sales(5y)23.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-686.71%
EPS Next Y105%
EPS Next 2Y52.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.8%
Revenue growth 3Y29.94%
Revenue growth 5Y28.65%
Sales Q2Q%11.54%
Revenue Next Year24.32%
Revenue Next 2Y20.88%
Revenue Next 3Y16.2%
Revenue Next 5Y12.07%
EBIT growth 1Y-23.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year295.56%
EBIT Next 3Y76.02%
EBIT Next 5Y54.55%
FCF growth 1Y49.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.1%
OCF growth 3YN/A
OCF growth 5YN/A
FACEPHI BIOMETRIA SA / ALPHI.PA FAQ
What is the fundamental rating for ALPHI stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALPHI.PA.
What is the valuation status of FACEPHI BIOMETRIA SA (ALPHI.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to FACEPHI BIOMETRIA SA (ALPHI.PA). This can be considered as Overvalued.
What is the profitability of ALPHI stock?
FACEPHI BIOMETRIA SA (ALPHI.PA) has a profitability rating of 1 / 10.
What is the expected EPS growth for FACEPHI BIOMETRIA SA (ALPHI.PA) stock?
The Earnings per Share (EPS) of FACEPHI BIOMETRIA SA (ALPHI.PA) is expected to grow by 105% in the next year.
Is the dividend of FACEPHI BIOMETRIA SA sustainable?
The dividend rating of FACEPHI BIOMETRIA SA (ALPHI.PA) is 0 / 10 and the dividend payout ratio is 0%.